Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

Journal of Clinical Pharmacology - Tập 55 Số 9 - Trang 1012-1023 - 2015
Linh T. Nguyen1, Jaymes Holland1, Dale Miles1, Caroline Engel2, Natacha Benrimoh2, Terry O’Reilly3, Steven Lacy1
1Exelixis, Inc.; So. San Francisco CA USA
2Celerion, Montreal, Quebec, Canada.
3Celerion, Tempe, AZ, USA

Tóm tắt

AbstractCabozantinib is a small‐molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with progressive, metastatic medullary thyroid cancer. In vitro data indicate that (1) cytochrome P450 (CYP) 3A4 is the primary CYP isoenzyme involved in the metabolism of cabozantinib, and (2) CYP2C8 is the CYP isoenzyme most potently inhibited by cabozantinib with potential for in vivo inhibition at clinically relevant plasma exposures. Pharmacokinetic (PK) drug–drug interactions (DDIs) were evaluated clinically between cabozantinib and (1) a CYP3A inducer (rifampin) in healthy volunteers, (2) a CYP3A inhibitor (ketoconazole) in healthy volunteers, and (3) a CYP2C8 substrate (rosiglitazone) in patients with solid tumors. Compared with cabozantinib given alone, coadministration with rifampin resulted in a 4.3‐fold higher plasma clearance (CL/F) of cabozantinib and a 77% decrease in cabozantinib plasma AUC0–inf, whereas coadministration with ketoconazole decreased cabozantinib CL/F by 29% and increased cabozantinib AUC0–inf by 38%. Chronic coadministration with cabozantinib resulted in no significant effect on rosiglitazone plasma Cmax, AUC0–24, or AUC0–inf. In summary, chronic use of strong CYP3A inducers and inhibitors should be avoided when cabozantinib is administered, and cabozantinib at clinically relevant exposures is not anticipated to markedly affect the PK of concomitant medications via CYP enzyme inhibition.

Từ khóa


Tài liệu tham khảo

COMETRIQ™ (cabozantinib) capsules. US Prescribing Information. Exelixis Inc. November2012.

Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) for cabozantinib (COMETRIQ).2012.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203756Orig1s000ClinPharmR.pdf. Accessed July 14 2014.

10.1089/thy.2014.0125

10.1093/annonc/mdu184

10.1007/BF01061471

Cabanillas ME, 2012, Anti‐tumor activity observed in a cohort of patients (pts) with differentiated thyroid cancer (DTC) in a Phase 1 study of cabozantinib (XL184) [abstract 5547], J Clin Oncol., 30, 10.1200/jco.2012.30.15_suppl.5547

10.2165/00003088-200342090-00003

US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for Industry. Drug interaction studies — study design data analysis and implications for dosing and labeling. Draft Guidance.2006.

10.1038/clpt.1992.3

10.1038/clpt.1992.140

Micuda S, 2007, Diurnal variation of 6beta‐hydroxycortisol in cardiac patients, Physiol Res, 56, 307, 10.33549/physiolres.931029

10.1177/009127009903900508

10.2165/00003088-200544100-00005

10.1007/s00280-003-0722-9

10.1016/j.critrevonc.2013.08.007

10.1007/BF00561021

10.2165/00003088-200038020-00002

10.1124/dmd.105.008730

10.1177/0091270008325931

10.1007/s00280-004-0832-z

10.1007/s10637-010-9511-6

10.1002/jcph.109

US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for Industry: in vivo drug metabolism/drug interaction studies — study design data analysis implications for dosing and labeling recommendations.2012.

US Food and Drug Administration. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to restrict access to rosiglitazone‐containing medicines including avandia avandamet and avandaryl. May 18 2011.http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm. Accessed July 14 2014.

10.1200/JCO.2010.32.4145

10.1056/NEJMoa060655

10.1016/S0140-6736(11)61613-9

10.1056/NEJMoa1303989

10.1200/JCO.2008.20.1293

Thông tin
Thông tin xuất bản

Journal of Clinical Pharmacology

Tập 55 Số 9

1012-1023

Thông tin tác giả